Login or Register to view
Using NanoCelle® drug delivery technologies to enhance patient benefits
Transaction Summary
Medlab Clinical Ltd
-
ASX : MDC
Investment Highlights
-
Innovative medicine delivery platform (NanoCelle®) which is patented in North America, Europe, Australia, New Zealand and parts of Asia until 2036
-
Strong datapoints on NanaBis™ for cancer bone pain as an investigational new drug
-
Compassionate use (pre-revenue optionality) available in AU and UK to special needs patients ahead of final Regulatory drug approval
-
Finalising CMC package for NanaBis™ in US ahead of proposed FDA meetings, using drug substance drug master files, and packaging device master files. Possible US FDA 505(b)(2) [abbreviated pathway] option.
-
The Australian Government has committed up to AU$12M in R&D rebates over next few years to the NanaBis™ program.
Company Overview
MEDLAB CLINICAL LTD (ASX:MDC) focuses on clinical indications that the Company believes represent unmet or inadequately addressed medical needs and represents compelling commercial opportunities.
Core to this undertaking is NanoCelle® a Patented pharmaceutical-delivery platform allowing for a more effective method of administering pharmaceutical products compared to the traditional methods, which include intravenous, intramuscular, subcutaneous, oral (ingested and sublingual), rectal and inhalation.
NanoCelle® has been shown to enhance both uptake and absorption of medicines. NanoCelle® is a principal component of NanaBis™, a cannabinoid-based medicine for future regulatory approval, and is allowed both in Australia and in the United Kingdom to be sold to special needs patients, also known as compassionate use, special access and/or named patient.
NanaBis™ published research is compelling, showing reduction in pain, improvements in patients’ quality of life and reduction of opioid use.
Medlab is:
-
Headquartered Sydney, Australia with laboratory co-located at the University of New South Wales
-
Extensive patent portfolio and ongoing grant recipient
-
36 Staff, covering science, medical and commercialisation in Australia, USA and UK.
-
ASX listed MDC, NASDAQ symbol reserved MDLB
-
NanoCelle® represent strong optionality for use in a wide variety of medicines (as per patents)
-
NanaBis™ data points show significant pain reduction, improvements in quality of life and reduction in opioid use
-
Therapeutic focus in cancer pain and mental health
-
Industry partnering discussion early but underway
Medlab is focused on patient outcomes and in tackling one of the largest healthcare problems of today – opioid use.
Edison valuation shows a 10x factor against current market cap. See record attached below.
Transaction Overview
ASX listed Capital Raising – details of offer subject to confidentiality
Additional Information
- Financials
- Company Presentations
- Other Documents
Team
- Management
- Directors
-
Kerem Kaya
CFO/Company Secretary
-
Ian Curtinsmith
CIO
-
Dr David Rutolo
Director of Science
-
Dr Jeremy Henson
Director of Research
-
Patrick Mueller
Director of Pharmacovigilance and Regulatory Affairs
-
Dr Sean Hall
CEO
-
Michael Hall
Non-Executive Chairperson
-
Drew Townsend
Non-Executive Director
-
Cheryl Maley
Non-Executive Director
-
Mohit Gupta
Non-Executive Director